Fluid OverloadNCT03677622
Restrictive or Doppler-guided Fluid Treatment in Colorectal Surgery
A study testing Voluven to near maximal stroke volume of the heart in people with Fluid Overload, run by Holbaek Sygehus.
Trial summary
This is a clinical randomised double blinded multicentre trial of two different fluid treatments during colorectal surgery in an enhanced recovery programme A restricted fluid regimen aiming at zero fluid balance and less than two kilograms bodyweight change was compared with another fluid regimen where intravenous… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Fluid Overload
- What is being tested?
- Voluven to near maximal stroke volume of the heart
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- No sites listed yet
- Study dates
- 1 Mar 2008to 31 Aug 2009
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- All patients scheduled for colorectal resections if it is preoperatively estimated that the surgery may be cancer radical.
- ASA level 1-4.
Who cannot join
- Emergency surgery,
- Alcohol consumption > 5 units daily,
- Inability to give informed consent (language problems, unconscious, psychosis (including confusion))
- Pregnant and lactating women
- Contraindication for the use of HES (severe renal impairment, allergy, severe bleeding disorders and pregnancy)
- Other non-radically treated malignant diseases
About this study
Official title: Which Goal for Fluid Therapy During Colorectal Surgery is Followed by the Best Outcome: Near Maximal Stroke Volume or Restricted Fluid Therapy
This is a clinical randomised double blinded multicentre trial of two different fluid treatments during colorectal surgery in an enhanced recovery programme A restricted fluid regimen aiming at zero fluid balance and less than two kilograms bodyweight change was compared with another fluid regimen where intravenous fluids were given to reach near maximal stroke volume of the heart, guided by a Doppler in the oesophagus.
The primary outcome was a composite outcome of postoperative complications and death.
Read more
Included was 150 patients undergoing elective colorectal surgery. No difference was found between the two groups. Both fluid therapies resulted in low complication rates. The difference in fluid volume between the groups was only 600 ml on the day of operation.
The results are published, see reference section.
Read the detailed description
Background Hypovolemia can cause postoperative complications, circulatory collapse and death, regardless if the cause is blood loss or loss of other fluids. Therefore, doctors are giving fluid intravenously to patients undergoing surgery, and often in an amount larger than the measured losses. Recent studies, however, have shown that also fluid overload plays a part in complication development after surgery (1-3). It is therefore important to find the optimal fluid treatment for surgical patients.
In Denmark, approximately 3500 patients are undergoing surgery every year for colorectal cancer, and in addition, operations are performed for benign diseases. However, the complication rate after colorectal surgery remains high (approximately 30%).
Disagreement about which fluid treatment is optimal exist between three "schools for fluid therapy":
- "Standard fluid therapy" which in addition to replacing external fluid loss (blood loss, urine and evaporation) include fluid to replace a "third space loss" and fluid to counteract low blood pressure (4-5). Standard therapy is poorly defined and differ between hospitals. It cause a bodyweight increase by 3-6 kilo (6-7).
- "Goal-directed fluid therapy", where volume is given in a bolus injection of a colloid (typically hydroxyethyl starch (HES)) in order to keep the patient's stroke volume (SV) at a near maximum level (1). The heart is brought close to maximum performance. In theory, hypovolemia is prevented and oxygen supply to the tissues increased. In the studies available, HES is given on top of "standard therapy" and "Goal-directed fluid therapy" therefore result in a weight gain not measured in the available studies.
- "Restrictive fluid therapy", replace only measurable fluid losses and strive to maintain the patient's normal (preoperative) body weight. The hypothesis is that excess fluid cause interstitial edema which may be harmful to the healing of tissue and function. (2,3,8). "Standard fluid therapy" is meaningful if a benefit exists in giving fluid to a possible third space loss and treat the vasodilatation caused by epidural analgesia by volume. However, a recent critical review of the literature poses serious doubts about the existence of a third space loss (9), and no beneficial effect of volume treatment of the vasodilatation caused by epidural analgesia been shown. "Goal-directed fluid therapy" tests the hypothesis that a near maximal stroke volume (SV) during surgery improves tissue oxygen supply, thus preventing the harmful effects of hypovolemia. Unfortunately, all studies that have tested "goal-directed fluid therapy" with esophageal Doppler monitoring have chosen to use a not well-defined "standard fluid regime" as their control group, and in the intervention groups they have chosen to first provide "standard fluid therapy" and then give a further HES to maximum stroke volume (10-16). In addition, length of hospital stay (LOS) were the primary endpoint not morbidity or mortality, and patients were not followed after discharge. The results of these studies differ. Most studies have shown shorter LOS in the intervention group, but only 3 of the studies have been blinded (11, 13, 16). Some studies have shown a lower complication rate in the intervention groups (12, 13, 16) some studies have not shown a difference in complication rate (10, 14, 15, 17) and some have raised suspicions that the intervention has been harmful, with increased mortality (15, 18). "Restrictive fluid treatment" is based on the following logic: If there is no third space loss, it is pointless to give saline to replace it, and if epidural vasodilatation is not corrected with volume, it is pointless to give fluid to increase BP. The hypothesis is that fluid overload might result in interstitial edema, harmful to tissue healing and cardiovascular function. Only a few studies have tested the effect of "restrictive fluid treatment" on the development of complications following major surgical procedures, but the results have been consistent: "Restrictive fluid treatment" has reduced the complication rate after elective abdominal surgery (2, 3). Purpose To investigate whether perioperative fluid therapy controlled by esophageal Doppler monitoring reduces postoperative complications compared to perioperative fluid therapy controlled by measuring external fluid loss and body weight. In addition, to investigate whether patients receiving "restrictive fluid therapy" develop hypovolemia with reduced SV during surgery. Design Clinical randomized double-blinded multicenter study, stratified for each center, and for laparoscopic and open surgery. This will result in a simultaneous stratification of combined epidural and general anesthesia (used in open surgery) and general anesthesia alone (as used in laparoscopic surgery). The patients are block randomized with a number of patients in each block unknown to the doctors performing the randomization. Several centers are participating to complete the trial within a reasonable time. The patients are following an enhanced recovery program in both arms. Material 150 patients undergoing elective colorectal resection will be included. The number was determined using data from complication databases, which shows a postoperative complication rate of approximately 30%. 2α is set at 5% and β is set at 15%, increasing the credibility of a possible negative result. A number of n > 67.5 patients in each group was calculated, and inclusion of 75 patients in each group (total 150 patients) was decided. Outcome The composite endpoint of mortality and postoperative complications is the primary endpoint. An event is accepted as a complication if it demands clinical treatment and fulfills given diagnostic criteria. Based on the following hypotheses; subgroup analysis are planned: Both hypovolemia and hypervolemia may be harmful to the cardiac function (low oxygen supply and congestion) and cause cardiovascular complications such as:
- Newly developed arrhythmias, AMI, pneumonia, pulmonary congestion, newly developed pleural exudation, pulmonary edema or ARDS. Both hypovolemia and hypervolemia may be harmful to tissue healing (low oxygen supply and interstitial edema) and cause complications related to tissue healing and infection:
- Infections of the wound, bursting of the wound (superficial and deep), leakage from the anastomosis and separation of a stoma. In addition, data for physiological changes in HR, BP, SV, Hemoglobin concentration, diuresis etc. will be analyzed. Method: A trial profile will account for all patients undergoing elective colorectal resections in the inclusion period. I.e. all patients undergoing elective colorectal resections must be consecutively screened for inclusion and asked to participate if no exclusion criteria is met. The information will take place the day before surgery. The information will be based on the written information (see appendix), and will be given in an easily understandable language and in an appropriate manner adapted to the individual. Patients are randomized to either "restrictive fluid treatment" (R group) or "fluid treatment to maximum SV" (SV group). Preoperative fluid treatment: All patients may drink until 2 hours before anesthesia. If supplemental intravenous fluids are needed, it is given in accordance with the loss, i.e.: Glucose isotonic (5%) replaces insensible perspiration (if diabetes insulin and if needed potassium is added). Registration of fluid intake begins at midnight on the day of the operation. Perioperative monitoring: Standard anesthesia monitoring as recommended by the Danish Anesthesiological Society is used. A catheter in the radial artery monitor the BP and is used for blood sampling. BP and HR are measured at least 3 times before induction of anesthesia and every five minutes during anesthesia. Immediately after the induction of anesthesia, all patients have a Doppler placed in the esophagus to measure the flow rate in the aorta, thereby calculating the stroke volume (SV). The SV is measured before surgery is started, and every 15 minutes throughout the operation. In the "Restrictive Group", the Doppler measurements are recorded to a black box (see later). Anesthesia: Routine premedication is given. In open surgery, combined epidural and general anesthesia are used: The Epidural catheter is inserted at the Th8-Th10 level, tested, and a continuous infusion of Bupivacaine 0.5% is running until sufficient blockade. General anesthesia is induced with Thiopental / Propofol, Fentanyl and Rocuronium (Esmerone®) for a neuromuscular blockade. Anesthesia is maintained with Sevoflurane / Fentanyl or Propofol / Remifentanil (Ultiva®). For laparoscopic surgery, only general anesthesia is used. In case of conversion from laparoscopic to open surgery, an epidural catheter is placed postoperatively. Perioperative fluid treatment: If the preoperative fluid intake <500 ml. it is supplemented to 500 ml. with saline in both groups. In addition, saline is given with the medicine. Lost blood is replaced volume by volume with HES (Voluven ®) with an allowance of 500 ml extra. In the SV group, a bolus injection of 200 ml Voluven® is given until the increase in SV is <10%. Blinding: Only the anesthesiologist know the randomization group and perioperative fluid treatment. It is unknown to the patient and to the project surgeon. As all patients in the study will receive NaCl 0.9%, Voluven ®, and other IV fluids, and as all patients are monitored with a Doppler in the esophagus, effective blinding of the surgeons can be achieved. In order to avoid bias of the anesthesiologist, the SV measurements are recorded to a black box in the restrictive group. Postoperative fluid treatment: Throughout the rest of the day of the operation, fluid is given to meet the basic needs, i.e. approx. 1000 ml K-Na-glucose, K-glucose or glucose 5%. The patient is encouraged to drink and eat as soon as it is safe to swallow. Nutrition is started as soon as possible (preferably in recovery) with protein drinks. In the surgical department, fluid charts and weight changes, allowing a body weight increase of two kilograms without treatment, monitor fluid treatment. If the weight increases more than two kilogram, furosemide is given to increase the diuresis. The patient's body weight is measured in the morning before surgery, and then every morning until discharge or the seventh post-operative day. The same set of scales are used throughout the course. Blood tests: Venous blood is taken in the morning on the day of the operation and every morning the following 5 days or until the patient is discharged. Surgery: Patients are operated with either open or laparoscopic technique. Antibiotic prophylaxis follows the department's routine. The bowel is not cleansed except for an enema before rectal surgery. Postoperative analgesia: In open surgical procedures, continuous, patient-controlled, epidural analgesia is given for a maximum of 4 days. In addition 1 g Paracetamol is given x 3-4, and / or Ibuprofen 400 mg x 3-4 if there are no contraindications. Supplemental Morphine p.n. is allowed. Nausea is treated with Ondansetron, Metoclopramide or DHB, depending on the cause of the patient's nausea. In case of suspicion of ventricular retention, a ventricular tube is applied for suction. Data collection The project doctor or surgeon see the patient every day and evaluates the patient's condition, prescribes fluid treatment, and assesses the presence and treatment of any complications. In addition, the patient is visiting the outpatient clinic approximately 30 days postoperatively. Any complications after discharge is recorded. Analysis The following analysis are planned:
- "Intention-to-treat analysis" analyses all included patients for the primary endpoint.
- "Per-protocol analysis" analyses those patients who have not been excluded following randomization (to be completed at > 10 exclusions only)
- Analyzes of the above subgroups.
- Analysis of the physiological data
- Conditions
- Fluid Overload
- Being tested
- Voluven to near maximal stroke volume of the heart
- Keywords
- Restricted fluid therapy, Goal directed fluid therapy, Colorectal surgery, Surgery, Enhanced recovery, Fluid therapy
- Medical subject headings
- Edema
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Voluven to near maximal stroke volume of the heartDrug
Stroke volume guided fluid treatment with Voluven on the basis of restricted fluid therapy
| Study group | Role | What they receive |
|---|---|---|
| Stroke volume (SV) group | Experimental | As bellow but with the addition of HES (Voluven (R)) to near maximal stroke volume of the heart:
A bolus injection of 200 ml Voluven® is given repeatedly with measurement of the SV until the increase in SV in response to the bolus is <10%.
The Case Report File give detailed instructions for the interpretation of the SV during changes in position of the patient during laparoscopic surgery. Receives: Drug: Voluven to near maximal stroke volume of the heart |
| Restricted group | Active comparator | Preoperatively: Clear oral fluids until 2 h before surgery. During surgery: If preoperative fluid intake <500 ml, NaCl 0.9% is given until 500 ml.
Lost blood is replaced volume by volume with HES (Voluven®) with allowance of 500 ml extra.
Postoperative fluid: The rest of the day of surgery, fluid is given to meet the basic needs, i.e. 1000 ml K-Na-glucose, K-glucose or glucose 5%. The patient is encouraged to drink and eat as soon possible.
In the surgical department, fluid charts and weight changes monitor fluid balance. A body weight increase of two kilograms is allowed.
Fluid losses is replaced with a fluid having a similar electrolyte composition as the loss and in an equal volume. If the weight increases more than two kilogram, furosemide is given to increase the diuresis. Receives: Drug: Voluven to near maximal stroke volume of the heart |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with a postoperative complication
Only complications demanding surgical or medical treatment. Diagnostic criteria for each complication was given by protocol
Measured: 30 day follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2018
- Study start1 Mar 2008
- Primary completion31 Jul 2009
- Study completion31 Aug 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (16)Papers the sponsor has linked to this study.
- Other trials for Fluid OverloadStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 150 participants (actual)
Sponsor and investigators
- Lead sponsor
- Holbaek Sygehus
- Sponsor type
- University, hospital or other
- Collaborators
- Bispebjerg Hospital, Glostrup University Hospital, Copenhagen, Aarhus University Hospital, Vejle Hospital, Svendborg Hospital
- Responsible party
- Principal investigator, Birgitte Brandstrup, Holbaek Sygehus
- Investigators
- Birgitte Brandstrup, PhD, Principal investigator, Holbaek Sygehus
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03677622
- Sponsor's protocol ID
- 2
- Status last verified
- Oct 2018
- First submitted
- 18 Sep 2018
- Last updated
- 5 Oct 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: No plan
Publications
Brandstrup B, Engquist A. [Is postoperative mortality affected by liberal intravenous fluid therapy? Presentation of a Cochrane analysis and a literature review]. Ugeskr Laeger. 2003 Mar 24;165(13):1342-5. No abstract available. Danish.
PubMed 12703278Brandstrup B, Tonnesen H, Beier-Holgersen R, Hjortso E, Ording H, Lindorff-Larsen K, Rasmussen MS, Lanng C, Wallin L, Iversen LH, Gramkow CS, Okholm M, Blemmer T, Svendsen PE, Rottensten HH, Thage B, Riis J, Jeppesen IS, Teilum D, Christensen AM, Graungaard B, Pott F; Danish Study Group on Perioperative Fluid Therapy. Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial. Ann Surg. 2003 Nov;238(5):641-8. doi: 10.1097/01.sla.0000094387.50865.23.
PubMed 14578723Nisanevich V, Felsenstein I, Almogy G, Weissman C, Einav S, Matot I. Effect of intraoperative fluid management on outcome after intraabdominal surgery. Anesthesiology. 2005 Jul;103(1):25-32. doi: 10.1097/00000542-200507000-00008.
PubMed 15983453Lobo DN, Stanga Z, Simpson JA, Anderson JA, Rowlands BJ, Allison SP. Dilution and redistribution effects of rapid 2-litre infusions of 0.9% (w/v) saline and 5% (w/v) dextrose on haematological parameters and serum biochemistry in normal subjects: a double-blind crossover study. Clin Sci (Lond). 2001 Aug;101(2):173-9.
PubMed 11473492Rasmussen LA, Rosenberg J, Crawford ME, Kehlet H. [Perioperative fluid therapy. A quality control study]. Ugeskr Laeger. 1996 Sep 16;158(38):5286-90. Danish.
PubMed 8966776Lobo DN, Bostock KA, Neal KR, Perkins AC, Rowlands BJ, Allison SP. Effect of salt and water balance on recovery of gastrointestinal function after elective colonic resection: a randomised controlled trial. Lancet. 2002 May 25;359(9320):1812-8. doi: 10.1016/S0140-6736(02)08711-1.
PubMed 12044376Brandstrup B, Svensen C, Engquist A. Hemorrhage and operation cause a contraction of the extracellular space needing replacement--evidence and implications? A systematic review. Surgery. 2006 Mar;139(3):419-32. doi: 10.1016/j.surg.2005.07.035.
PubMed 16546507Conway DH, Mayall R, Abdul-Latif MS, Gilligan S, Tackaberry C. Randomised controlled trial investigating the influence of intravenous fluid titration using oesophageal Doppler monitoring during bowel surgery. Anaesthesia. 2002 Sep;57(9):845-9. doi: 10.1046/j.1365-2044.2002.02708.x.
PubMed 12190747Gan TJ, Soppitt A, Maroof M, el-Moalem H, Robertson KM, Moretti E, Dwane P, Glass PS. Goal-directed intraoperative fluid administration reduces length of hospital stay after major surgery. Anesthesiology. 2002 Oct;97(4):820-6. doi: 10.1097/00000542-200210000-00012.
PubMed 12357146Mythen MG, Webb AR. Perioperative plasma volume expansion reduces the incidence of gut mucosal hypoperfusion during cardiac surgery. Arch Surg. 1995 Apr;130(4):423-9. doi: 10.1001/archsurg.1995.01430040085019.
PubMed 7535996Noblett SE, Snowden CP, Shenton BK, Horgan AF. Randomized clinical trial assessing the effect of Doppler-optimized fluid management on outcome after elective colorectal resection. Br J Surg. 2006 Sep;93(9):1069-76. doi: 10.1002/bjs.5454.
PubMed 16888706Sinclair S, James S, Singer M. Intraoperative intravascular volume optimisation and length of hospital stay after repair of proximal femoral fracture: randomised controlled trial. BMJ. 1997 Oct 11;315(7113):909-12. doi: 10.1136/bmj.315.7113.909.
PubMed 9361539Venn R, Steele A, Richardson P, Poloniecki J, Grounds M, Newman P. Randomized controlled trial to investigate influence of the fluid challenge on duration of hospital stay and perioperative morbidity in patients with hip fractures. Br J Anaesth. 2002 Jan;88(1):65-71. doi: 10.1093/bja/88.1.65.
PubMed 11881887Wakeling HG, McFall MR, Jenkins CS, Woods WG, Miles WF, Barclay GR, Fleming SC. Intraoperative oesophageal Doppler guided fluid management shortens postoperative hospital stay after major bowel surgery. Br J Anaesth. 2005 Nov;95(5):634-42. doi: 10.1093/bja/aei223. Epub 2005 Sep 9.
PubMed 16155038Price JD, Sear JW, Venn RM. Perioperative fluid volume optimization following proximal femoral fracture. Cochrane Database Syst Rev. 2004;(1):CD003004. doi: 10.1002/14651858.CD003004.pub2.
PubMed 14974001
Study at a glance
From the registry record, last updated by the sponsor on 5 Oct 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Which Goal for Fluid Therapy During Colorectal Surgery is Followed by the Best Outcome: Near Maximal Stroke Volume or Restricted Fluid Therapy
- ClinicalTrials.gov ID
- NCT03677622
- Acronym / sponsor ID
- 2
- Conditions
- Fluid Overload
- Keywords
- Restricted fluid therapy, Goal directed fluid therapy, Colorectal surgery, Surgery, Enhanced recovery, Fluid therapy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 150 participants (actual)
- Lead sponsor
- Holbaek SygehusUniversity, hospital or other
- Collaborators
- Bispebjerg Hospital, Glostrup University Hospital, Copenhagen, Aarhus University Hospital, Vejle Hospital, Svendborg Hospital
- Study start
- 1 Mar 2008 (actual)
- Primary completion
- 31 Jul 2009 (actual)
- Study completion
- 31 Aug 2009 (actual)
- First posted
- 19 Sep 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a clinical randomised double blinded multicentre trial of two different fluid treatments during colorectal surgery in an enhanced recovery programme A restricted fluid regimen aiming at zero fluid balance and less than two kilograms bodyweight change was compared with another fluid regimen where intravenous fluids were given to reach near maximal stroke volume of the heart, guided by a Doppler in the oesophagus.
The primary outcome was a composite outcome of postoperative complications and death.
Included was 150 patients undergoing elective colorectal surgery. No difference was found between the two groups. Both fluid therapies resulted in low complication rates. The difference in fluid volume between the groups was only 600 ml on the day of operation.
The results are published, see reference section.
Detailed description
Background Hypovolemia can cause postoperative complications, circulatory collapse and death, regardless if the cause is blood loss or loss of other fluids. Therefore, doctors are giving fluid intravenously to patients undergoing surgery, and often in an amount larger than the measured losses. Recent studies, however, have shown that also fluid overload plays a part in complication development after surgery (1-3). It is therefore important to find the optimal fluid treatment for surgical patients.
In Denmark, approximately 3500 patients are undergoing surgery every year for colorectal cancer, and in addition, operations are performed for benign diseases. However, the complication rate after colorectal surgery remains high (approximately 30%).
Disagreement about which fluid treatment is optimal exist between three "schools for fluid therapy":
- "Standard fluid therapy" which in addition to replacing external fluid loss (blood loss, urine and evaporation) include fluid to replace a "third space loss" and fluid to counteract low blood pressure (4-5). Standard therapy is poorly defined and differ between hospitals. It cause a bodyweight increase by 3-6 kilo (6-7).
- "Goal-directed fluid therapy", where volume is given in a bolus injection of a colloid (typically hydroxyethyl starch (HES)) in order to keep the patient's stroke volume (SV) at a near maximum level (1). The heart is brought close to maximum performance. In theory, hypovolemia is prevented and oxygen supply to the tissues increased. In the studies available, HES is given on top of "standard therapy" and "Goal-directed fluid therapy" therefore result in a weight gain not measured in the available studies.
- "Restrictive fluid therapy", replace only measurable fluid losses and strive to maintain the patient's normal (preoperative) body weight. The hypothesis is that excess fluid cause interstitial edema which may be harmful to the healing of tissue and function. (2,3,8). "Standard fluid therapy" is meaningful if a benefit exists in giving fluid to a possible third space loss and treat the vasodilatation caused by epidural analgesia by volume. However, a recent critical review of the literature poses serious doubts about the existence of a third space loss (9), and no beneficial effect of volume treatment of the vasodilatation caused by epidural analgesia been shown. "Goal-directed fluid therapy" tests the hypothesis that a near maximal stroke volume (SV) during surgery improves tissue oxygen supply, thus preventing the harmful effects of hypovolemia. Unfortunately, all studies that have tested "goal-directed fluid therapy" with esophageal Doppler monitoring have chosen to use a not well-defined "standard fluid regime" as their control group, and in the intervention groups they have chosen to first provide "standard fluid therapy" and then give a further HES to maximum stroke volume (10-16). In addition, length of hospital stay (LOS) were the primary endpoint not morbidity or mortality, and patients were not followed after discharge. The results of these studies differ. Most studies have shown shorter LOS in the intervention group, but only 3 of the studies have been blinded (11, 13, 16). Some studies have shown a lower complication rate in the intervention groups (12, 13, 16) some studies have not shown a difference in complication rate (10, 14, 15, 17) and some have raised suspicions that the intervention has been harmful, with increased mortality (15, 18). "Restrictive fluid treatment" is based on the following logic: If there is no third space loss, it is pointless to give saline to replace it, and if epidural vasodilatation is not corrected with volume, it is pointless to give fluid to increase BP. The hypothesis is that fluid overload might result in interstitial edema, harmful to tissue healing and cardiovascular function. Only a few studies have tested the effect of "restrictive fluid treatment" on the development of complications following major surgical procedures, but the results have been consistent: "Restrictive fluid treatment" has reduced the complication rate after elective abdominal surgery (2, 3). Purpose To investigate whether perioperative fluid therapy controlled by esophageal Doppler monitoring reduces postoperative complications compared to perioperative fluid therapy controlled by measuring external fluid loss and body weight. In addition, to investigate whether patients receiving "restrictive fluid therapy" develop hypovolemia with reduced SV during surgery. Design Clinical randomized double-blinded multicenter study, stratified for each center, and for laparoscopic and open surgery. This will result in a simultaneous stratification of combined epidural and general anesthesia (used in open surgery) and general anesthesia alone (as used in laparoscopic surgery). The patients are block randomized with a number of patients in each block unknown to the doctors performing the randomization. Several centers are participating to complete the trial within a reasonable time. The patients are following an enhanced recovery program in both arms. Material 150 patients undergoing elective colorectal resection will be included. The number was determined using data from complication databases, which shows a postoperative complication rate of approximately 30%. 2α is set at 5% and β is set at 15%, increasing the credibility of a possible negative result. A number of n > 67.5 patients in each group was calculated, and inclusion of 75 patients in each group (total 150 patients) was decided. Outcome The composite endpoint of mortality and postoperative complications is the primary endpoint. An event is accepted as a complication if it demands clinical treatment and fulfills given diagnostic criteria. Based on the following hypotheses; subgroup analysis are planned: Both hypovolemia and hypervolemia may be harmful to the cardiac function (low oxygen supply and congestion) and cause cardiovascular complications such as:
- Newly developed arrhythmias, AMI, pneumonia, pulmonary congestion, newly developed pleural exudation, pulmonary edema or ARDS. Both hypovolemia and hypervolemia may be harmful to tissue healing (low oxygen supply and interstitial edema) and cause complications related to tissue healing and infection:
- Infections of the wound, bursting of the wound (superficial and deep), leakage from the anastomosis and separation of a stoma. In addition, data for physiological changes in HR, BP, SV, Hemoglobin concentration, diuresis etc. will be analyzed. Method: A trial profile will account for all patients undergoing elective colorectal resections in the inclusion period. I.e. all patients undergoing elective colorectal resections must be consecutively screened for inclusion and asked to participate if no exclusion criteria is met. The information will take place the day before surgery. The information will be based on the written information (see appendix), and will be given in an easily understandable language and in an appropriate manner adapted to the individual. Patients are randomized to either "restrictive fluid treatment" (R group) or "fluid treatment to maximum SV" (SV group). Preoperative fluid treatment: All patients may drink until 2 hours before anesthesia. If supplemental intravenous fluids are needed, it is given in accordance with the loss, i.e.: Glucose isotonic (5%) replaces insensible perspiration (if diabetes insulin and if needed potassium is added). Registration of fluid intake begins at midnight on the day of the operation. Perioperative monitoring: Standard anesthesia monitoring as recommended by the Danish Anesthesiological Society is used. A catheter in the radial artery monitor the BP and is used for blood sampling. BP and HR are measured at least 3 times before induction of anesthesia and every five minutes during anesthesia. Immediately after the induction of anesthesia, all patients have a Doppler placed in the esophagus to measure the flow rate in the aorta, thereby calculating the stroke volume (SV). The SV is measured before surgery is started, and every 15 minutes throughout the operation. In the "Restrictive Group", the Doppler measurements are recorded to a black box (see later). Anesthesia: Routine premedication is given. In open surgery, combined epidural and general anesthesia are used: The Epidural catheter is inserted at the Th8-Th10 level, tested, and a continuous infusion of Bupivacaine 0.5% is running until sufficient blockade. General anesthesia is induced with Thiopental / Propofol, Fentanyl and Rocuronium (Esmerone®) for a neuromuscular blockade. Anesthesia is maintained with Sevoflurane / Fentanyl or Propofol / Remifentanil (Ultiva®). For laparoscopic surgery, only general anesthesia is used. In case of conversion from laparoscopic to open surgery, an epidural catheter is placed postoperatively. Perioperative fluid treatment: If the preoperative fluid intake <500 ml. it is supplemented to 500 ml. with saline in both groups. In addition, saline is given with the medicine. Lost blood is replaced volume by volume with HES (Voluven ®) with an allowance of 500 ml extra. In the SV group, a bolus injection of 200 ml Voluven® is given until the increase in SV is <10%. Blinding: Only the anesthesiologist know the randomization group and perioperative fluid treatment. It is unknown to the patient and to the project surgeon. As all patients in the study will receive NaCl 0.9%, Voluven ®, and other IV fluids, and as all patients are monitored with a Doppler in the esophagus, effective blinding of the surgeons can be achieved. In order to avoid bias of the anesthesiologist, the SV measurements are recorded to a black box in the restrictive group. Postoperative fluid treatment: Throughout the rest of the day of the operation, fluid is given to meet the basic needs, i.e. approx. 1000 ml K-Na-glucose, K-glucose or glucose 5%. The patient is encouraged to drink and eat as soon as it is safe to swallow. Nutrition is started as soon as possible (preferably in recovery) with protein drinks. In the surgical department, fluid charts and weight changes, allowing a body weight increase of two kilograms without treatment, monitor fluid treatment. If the weight increases more than two kilogram, furosemide is given to increase the diuresis. The patient's body weight is measured in the morning before surgery, and then every morning until discharge or the seventh post-operative day. The same set of scales are used throughout the course. Blood tests: Venous blood is taken in the morning on the day of the operation and every morning the following 5 days or until the patient is discharged. Surgery: Patients are operated with either open or laparoscopic technique. Antibiotic prophylaxis follows the department's routine. The bowel is not cleansed except for an enema before rectal surgery. Postoperative analgesia: In open surgical procedures, continuous, patient-controlled, epidural analgesia is given for a maximum of 4 days. In addition 1 g Paracetamol is given x 3-4, and / or Ibuprofen 400 mg x 3-4 if there are no contraindications. Supplemental Morphine p.n. is allowed. Nausea is treated with Ondansetron, Metoclopramide or DHB, depending on the cause of the patient's nausea. In case of suspicion of ventricular retention, a ventricular tube is applied for suction. Data collection The project doctor or surgeon see the patient every day and evaluates the patient's condition, prescribes fluid treatment, and assesses the presence and treatment of any complications. In addition, the patient is visiting the outpatient clinic approximately 30 days postoperatively. Any complications after discharge is recorded. Analysis The following analysis are planned:
- "Intention-to-treat analysis" analyses all included patients for the primary endpoint.
- "Per-protocol analysis" analyses those patients who have not been excluded following randomization (to be completed at > 10 exclusions only)
- Analyzes of the above subgroups.
- Analysis of the physiological data
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Stroke volume (SV) group | Experimental | Drug: Voluven to near maximal stroke volume of the heartAs bellow but with the addition of HES (Voluven (R)) to near maximal stroke volume of the heart: A bolus injection of 200 ml Voluven® is given repeatedly with measurement of the SV until the increase in SV in response to the bolus is <10%. The Case Report File give detailed instructions for the interpretation of the SV during changes in position of the patient during laparoscopic surgery. |
| Restricted group | Active comparator | Drug: Voluven to near maximal stroke volume of the heartPreoperatively: Clear oral fluids until 2 h before surgery. During surgery: If preoperative fluid intake <500 ml, NaCl 0.9% is given until 500 ml. Lost blood is replaced volume by volume with HES (Voluven®) with allowance of 500 ml extra. Postoperative fluid: The rest of the day of surgery, fluid is given to meet the basic needs, i.e. 1000 ml K-Na-glucose, K-glucose or glucose 5%. The patient is encouraged to drink and eat as soon possible. In the surgical department, fluid charts and weight changes monitor fluid balance. A body weight increase of two kilograms is allowed. Fluid losses is replaced with a fluid having a similar electrolyte composition as the loss and in an equal volume. If the weight increases more than two kilogram, furosemide is given to increase the diuresis. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- All patients scheduled for colorectal resections if it is preoperatively estimated that the surgery may be cancer radical.
- ASA level 1-4.
Key exclusion criteria (6 listed)
- Emergency surgery,
- Alcohol consumption > 5 units daily,
- Inability to give informed consent (language problems, unconscious, psychosis (including confusion))
- Pregnant and lactating women
- Contraindication for the use of HES (severe renal impairment, allergy, severe bleeding disorders and pregnancy)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Voluven to near maximal stroke volume of the heartStroke volume guided fluid treatment with Voluven on the basis of restricted fluid therapy | Drug | Restricted group, Stroke volume (SV) group |
Primary outcome
Number of participants with a postoperative complication
Time frame: 30 day follow-up
Only complications demanding surgical or medical treatment. Diagnostic criteria for each complication was given by protocol
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Oct 2018.
- Background: PubMed 12703278Brandstrup B, Engquist A. [Is postoperative mortality affected by liberal intravenous fluid therapy? Presentation of a Cochrane analysis and a literature review]. Ugeskr Laeger. 2003 Mar 24;165(13):1342-5. No abstract available. Danish.
- Background: PubMed 14578723Brandstrup B, Tonnesen H, Beier-Holgersen R, Hjortso E, Ording H, Lindorff-Larsen K, Rasmussen MS, Lanng C, Wallin L, Iversen LH, Gramkow CS, Okholm M, Blemmer T, Svendsen PE, Rottensten HH, Thage B, Riis J, Jeppesen IS, Teilum D, Christensen AM, Graungaard B, Pott F; Danish Study Group on Perioperative Fluid Therapy. Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial. Ann Surg. 2003 Nov;238(5):641-8. doi: 10.1097/01.sla.0000094387.50865.23.
- Background: PubMed 15983453Nisanevich V, Felsenstein I, Almogy G, Weissman C, Einav S, Matot I. Effect of intraoperative fluid management on outcome after intraabdominal surgery. Anesthesiology. 2005 Jul;103(1):25-32. doi: 10.1097/00000542-200507000-00008.
- Background: PubMed 11473492Lobo DN, Stanga Z, Simpson JA, Anderson JA, Rowlands BJ, Allison SP. Dilution and redistribution effects of rapid 2-litre infusions of 0.9% (w/v) saline and 5% (w/v) dextrose on haematological parameters and serum biochemistry in normal subjects: a double-blind crossover study. Clin Sci (Lond). 2001 Aug;101(2):173-9.
- Background: PubMed 8966776Rasmussen LA, Rosenberg J, Crawford ME, Kehlet H. [Perioperative fluid therapy. A quality control study]. Ugeskr Laeger. 1996 Sep 16;158(38):5286-90. Danish.
- Background: PubMed 12044376Lobo DN, Bostock KA, Neal KR, Perkins AC, Rowlands BJ, Allison SP. Effect of salt and water balance on recovery of gastrointestinal function after elective colonic resection: a randomised controlled trial. Lancet. 2002 May 25;359(9320):1812-8. doi: 10.1016/S0140-6736(02)08711-1.
- Background: PubMed 16546507Brandstrup B, Svensen C, Engquist A. Hemorrhage and operation cause a contraction of the extracellular space needing replacement--evidence and implications? A systematic review. Surgery. 2006 Mar;139(3):419-32. doi: 10.1016/j.surg.2005.07.035.
- Background: PubMed 12190747Conway DH, Mayall R, Abdul-Latif MS, Gilligan S, Tackaberry C. Randomised controlled trial investigating the influence of intravenous fluid titration using oesophageal Doppler monitoring during bowel surgery. Anaesthesia. 2002 Sep;57(9):845-9. doi: 10.1046/j.1365-2044.2002.02708.x.
- Background: PubMed 12357146Gan TJ, Soppitt A, Maroof M, el-Moalem H, Robertson KM, Moretti E, Dwane P, Glass PS. Goal-directed intraoperative fluid administration reduces length of hospital stay after major surgery. Anesthesiology. 2002 Oct;97(4):820-6. doi: 10.1097/00000542-200210000-00012.
- Background: PubMed 7535996Mythen MG, Webb AR. Perioperative plasma volume expansion reduces the incidence of gut mucosal hypoperfusion during cardiac surgery. Arch Surg. 1995 Apr;130(4):423-9. doi: 10.1001/archsurg.1995.01430040085019.
- Background: PubMed 16888706Noblett SE, Snowden CP, Shenton BK, Horgan AF. Randomized clinical trial assessing the effect of Doppler-optimized fluid management on outcome after elective colorectal resection. Br J Surg. 2006 Sep;93(9):1069-76. doi: 10.1002/bjs.5454.
- Background: PubMed 9361539Sinclair S, James S, Singer M. Intraoperative intravascular volume optimisation and length of hospital stay after repair of proximal femoral fracture: randomised controlled trial. BMJ. 1997 Oct 11;315(7113):909-12. doi: 10.1136/bmj.315.7113.909.
- Textbook, reference number 4Link provided by the sponsor.
- Textbook, reference number 5Link provided by the sponsor.
- Individual participant dataSharing planned: Undecided. No plan
Related trials for Fluid Overload
Recruiting
Early Deresuscitation Strategy Driven by Tissue Perfusion in Renal Replacement Therapy in Patients With Acute Renal Failure
Acute Kidney Injury, Fluid Overload
Recruiting
Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System
Chronic Heart Failure, CKD Stage 3
Not yet recruitingPhase 4
Capital Offload-Shock
Hypervolemia, Cardiogenic Shock
Recruiting
Dry Weight Reduction Intervention Via Extra Ultrafiltration
Fluid Accumulation, Blood Pressure Management
Not yet recruiting
Bioimpedance and Multiparametric Ultrasound-Guided Fluid Management After Kidney Transplantation
Kidney Transplantation, Delayed Graft Function
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Birgitte Brandstrup, PhD principal investigator
Holbaek Sygehus
Questions about this trial
What is this clinical trial studying?
A study testing Voluven to near maximal stroke volume of the heart in people with Fluid Overload, run by Holbaek Sygehus.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Oct 2018. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants with a postoperative complication (time frame: 30 day follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03677622, which also lists 16 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2018.